Now showing items 1-2 of 2

    • A highly potent TACC3 inhibitor as a novel anticancer drug candidate 

      Akbulut, Özge; Lengerli, D.; Saatci, Özge; Duman, Elif; Şeker, Urartu Özgür Şafak; Işık, A.; Akyol, A.; Çalışkan, B.; Banoğlu, E.; Şahin, Özgür (NLM (Medline), 2020)
      TACC3, a transforming acidic coiled-coil (TACC) family member, is frequently upregulated in a broad spectrum of cancers, including breast cancer. It plays critical roles in protecting microtubule stability and centrosome ...
    • Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer 

      Saatçi, Ö.; Kaymak, A.; Raza, Umar; Ersan, Pelin G.; Akbulut, Özge; Banister, C. E.; Sikirzhytski, V.; Tokat, Ünal Metin; Aykut, Gamze; Ansari, Suhail A.; Tatlı-Doğan, H.; Doğan, M.; Jandaghi, P.; Işık, A.; Gündoğdu, F.; Kösemehmetoğlu, K.; Dizdar, Ö.; Aksoy, S.; Akyol, A.; Üner, A.; Buckhaults, P. J.; Riazalhosseini, Y.; Şahin, Özgür (Nature Research, 2020)
      Chemoresistance is a major obstacle in triple negative breast cancer (TNBC), the most aggressive breast cancer subtype. Here we identify hypoxia-induced ECM re-modeler, lysyl oxidase (LOX) as a key inducer of chemoresistance ...